Pennsylvania: A recent study is a classic example of how seemingly unlikely collaborators can
come together to make surprising discoveries. An international team of
gastroenterologists, pediatricians, natural products chemists, and
veterinarians, working with zebrafish models and mouse cell cultures
have discovered that a chemical found in Australian plants (including Pigweed) provides
insights into the cause of a rare and debilitating disorder affecting
newborns. This ailment, called biliary atresia (BA), is the most common
indication for a liver transplant in children.
The team isolated a plant toxin with a previously
uncharacterized chemical structure that causes biliary atresia in
zebrafish and mammals, noted collaborators Michael Pack, MD, a professor of Medicine in the Gastroenterology Division and the department of Cell and Developmental Biology, and Rebecca Wells, MD, an
associate professor of Medicine in the Gastroenterology Division and
the department of Pathology and Laboratory Medicine, both at the Perelman School of Medicine, University of Pennsylvania.
BA is a rapidly progressive and destructive disorder that affects
the cells lining the extra-hepatic bile duct. The cells within this
large duct, which carries bile from the liver to the small intestine,
are damaged as the result of an as-yet-unidentified environmental
insult, a toxin or infection, resulting in scarring (fibrosis) that
obliterates the duct, thus preventing bile flow.
The incidence of BA is 1/10,000 to 15,000 live births. It occurs
worldwide and is one of the most rapidly progressive forms of liver
cirrhosis and liver failure. Fortunately, a life-saving treatment for
BA is available for babies, a surgical procedure called a Kasai
portoenterostomy, in which a small segment of intestine is connected
directly to the liver, to restore bile flow. Most babies, though,
eventually develop cirrhosis of the liver and ultimately liver failure,
leading to the need for a transplant either in infancy, childhood or
adolescence.
Working with pediatric gastroenterologists Elizabeth Rand, MD and
David Piccoli, MD and other colleagues at the Fred and Suzanne Biesecker
Pediatric Liver Center at The Children’s Hospital of Philadelphia,
Pack and Wells became interested in a naturally occurring BA model
reported by veterinarians in Australia. During years of extreme drought
over the last four decades, sheep and cows grazed in unusual pastures
had given birth to offspring with a BA-like syndrome that was
essentially identical to human BA. Field veterinarian Steve Whittaker,
BVSc, and veterinary scientist Peter Windsor, DVSc, PhD, who diagnosed
BA in lambs during a drought in 2007, correlated the outbreaks with
ingestion of plants in the genus Dysphania, including a plant called pigweed, that grew on lands normally under water, suggesting a toxic cause of the animal BA
“The 2007 drought persisted through 2008, enabling us to harvest Dysphania species
plants from a pasture implicated in the 2007 episode,” recalls Wells,
who initiated the collaboration by contacting Whittaker soon after the
2007 outbreak and arranged to have the plant harvested and imported into
the U.S. “With the plant in hand, we knew we had a chance to identify
the responsible biliary toxins, guided by a zebrafish bioassay devised
in my laboratory,” adds Pack.
Collaborator and co-author John R. Porter, PhD, a natural products
chemist from the University of the Sciences in Philadelphia, made crude
extracts from the plants and in an iterative process, Pack used the
zebrafish bioassay to winnow this mixture containing thousands of
compounds down to a mixture of four compounds.
From this mixture, the team finally isolated a previously undescribed
isoflavone they called biliatresone. This toxin causes BA in five-day
old larval zebrafish, selectively destroying the bile ducts outside the
liver, but not inside the liver. The toxin also had no obvious effect
on any other of the fish tissues – similar to the findings in human BA.
Wells’ group showed that the plant toxin also has significant effects
on mammalian cells, causing changes in biliary cell structure and
organization that mimic changes in the afflicted human bile duct.
One of the perplexing qualities of the toxin is its specificity for
the large, extra-hepatic bile ducts. To better understand why other
liver cell types and smaller bile ducts were not affected, Pack
examined various zebrafish mutants, with the hope of finding one that
might be either more sensitive or resistant to bile duct injury.
Remarkably, his group was able to identify a mutant that was sensitized
to the toxin, and this mutation mapped to a region in the zebrafish
genome that is similar to an established human BA susceptibility region
found in a previous genome-wide study. This provided further evidence
that the Dysphania BA syndrome will be important for understanding human BA.
“Taken together, these findings provide direct evidence that BA
could be initiated by prenatal exposure to an environmental toxin,” say
Pack. And while it is clear that humans do not consume the pigweed or
related plants implicated in the sheep BA outbreaks, a non-toxic,
structurally related compound that co-purified with biliatresone is
found in beets, chard, and other consumable plants. The team is
currently studying whether gut bacteria can convert this inactive
compound into the active toxin.
Going forward, the researchers are attempting to synthesize a large
enough quantity of the toxin to study its effects in mice, which have a
liver and biliary system more closely related to humans than fish. In
addition, Pack and Wells will work with the models that they have
already established in their respective laboratories to determine the
toxin’s mechanism of action and understand how this can be used to
prevent and treat BA.
Kristin Lorent, Weilong Gong, Kyung A. Koo, Orith Waisbourd-Zinman,
Sara Karjoo, Xiao Zhao, Ian Sealy, Ross N. Kettleborough, Derek L.
Stemple, Peter A. Windsor, and Stephen J. Whittaker were additional
co-authors.
This work was supported in part by the UPenn NIH/NIDDK Center for
Molecular Studies in Digestive and Liver Diseases (P30DK050306,
R01DK092111) and the Fred and Suzanne Biesecker Pediatric Liver Center
at The Children’s Hospital of Philadelphia.